Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir

Inclusion Criteria: * Documented HIV-1 infection in female patients, age ≥18 years * Patients receiving antiretroviral therapy consisting of at least 2 antiretroviral agents other than protease inhibitor plus a ritonavir-boosted protease inhibitor (PI) for at least the previous 6 months * Plasma HIV viral load \<50 copies/ml on current boosted PI containing regimen for ≥ 6 months prior to study entry * Fasting LDL cholesterol \>130 mg/dl * Fasting triglycerides \<450 mg/dl Exclusion Criteria: * History of virological failure during previous antiretroviral therapy